Expedeon AG announced it has added ELISA-ONE(TM) to its product offering. The technology was developed by TGR BioSciences, which was acquired by Expedeon in May 2018. This product enables Expedeon to address new markets, such as the cell signalling market, at a critical time in the company's growth and development. The cell signalling market was reported to be $2.53 billion in 2017 and is forecast to reach $3.51 billion by 2022 at a CAGR of 6.8%.[1] The immunoassay market was estimated to be $1.6 to $1.7 billion in 2017 according to multiple reports. Amongst the market segments analysed, ELISA was found to be the most widely conducted immunoassay procedure according to one survey with the majority of users focusing on immunology, molecular biology, cell biology, biochemistry and cell signalling. From this could estimate that the addressable market for the ELISA-ONE is in the range of $300 million. ELISA-ONE(TM) next generation ready-to-use ELISA kits have been developed for fast detection of key intracellular proteins in major signalling pathways. Monitoring cell signalling pathways is essential for understanding many cellular processes and disease states and is therefore vital to help further basic research and drug discovery.